Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms

eLife

Volumn 5, Issue DECEMBER2016, 2016, Pages

  Kober, Daniel L ^a   Alexander Brett, Jennifer M ^a   Karch, Celeste M ^a   Cruchaga, Carlos ^a   Colonna, Marco ^a   Holtzman, Michael J ^a   Brett, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; MUTANT PROTEIN; TREM2 PROTEIN, HUMAN;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BONE DYSPLASIA; CIRCULAR DICHROISM; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DIFFERENTIAL SCANNING FLUORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; GEL FILTRATION CHROMATOGRAPHY; GENE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; NASU HAKOLA DISEASE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN STABILITY; SPECTROFLUOROMETRY; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 GENE; WESTERN BLOTTING; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; RECEPTORS, IMMUNOLOGIC;

EID: 85006873054     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.20391     Document Type: Article

References (69)

1. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica. Section D, Biological Crystallography 66:213-221. doi:10.1107/S0907444909052925,PMID:20124702
2. Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, Younkin S, Das P, Fryer JD, Bu G. 2015. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). The Journal of Biological Chemistry 290:26043-26050. doi:10.1074/jbc.M115.679043,PMID:26374899
3. Bailey CC, DeVaux LB, Farzan M. 2015. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. The Journal of Biological Chemistry 290:26033-26042. doi:10.1074/jbc.M115.677286,PMID:26374897
4. Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. 2014. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurology 71:449-453. doi:10.1001/jamaneurol.2013.6237,PMID:24535663
5. Cannon JP, O’Driscoll M, Litman GW. 2012. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics 64:39-47. doi:10.1007/s00251-011-0562-4,PMID:21800138
6. Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Me´ garbane´ A. 2008. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Human Mutation 29:E194-E204. doi:10.1002/humu.20836,PMID:18546367
7. Colonna M. 2003. DAP12 signaling: from immune cells to bone modeling and brain myelination. Journal of Clinical Investigation 111:313-314. doi:10.1172/JCI17745
8. Colonna M, Wang Y. 2016. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nature Reviews. Neuroscience 17:201-207. doi:10.1038/nrn.2016.7,PMID:26911435
9. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, et al. 2013. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. Neuron 78:256-268. doi:10.1016/j.neuron.2013.02.026,PMID:23562540
10. Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE. 2003. Pattern recognition by TREM-2: binding of anionic ligands. Journal of Immunology 171:594-599. doi:10.4049/jimmunol.171.2.594,PMID:12847223
11. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallographica. Section D, Biological Crystallography 66:486-501. doi:10.1107/S0907444910007493,PMID:20383002
12. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. PNAS 82:3197-3201. doi:10.1073/pnas.82.10.3197,PMID:3858816
13. Gattis JL, Washington AV, Chisholm MM, Quigley L, Szyk A, McVicar DW, Lubkowski J. 2006. The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment. The Journal of Biological Chemistry 281:13396-13403. doi:10.1074/jbc.M600489200,PMID:16505478
14. Golde TE, Streit WJ, Chakrabarty P. 2013. sAlzheimer. Alzheimer’s Research & Therapy 5:24. doi:10.1186/alzrt178,PMID:23692967
15. Guerreiro R, Bilgic B, Guven G, Brás J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M. 2013a. A novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiology of Aging 34:2890.e1-282890. doi:10.1016/j.neurobiolaging.2013.06.005
16. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, et al. 2013b. ’sTREM2 variants in Alzheimer. New England Journal of Medicine 368:117-127. doi:10.1056/NEJMoa1211851,PMID:23150934
17. Guerreiro RJ, Lohmann E, Brás JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. 2013c. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurology 70:78-84. doi:10.1001/jamaneurol.2013.579,PMID:23318515
18. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. 2006. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. Journal of Immunology 177:2051-2055. doi:10.4049/jimmunol.177.4.2051,PMID:16887962
19. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. 2009. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. Journal of Neurochemistry 109:1144-1156. doi:10.1111/j.1471-4159.2009.06042.x,PMID:19302484
20. Hubbard S, Thornton J. 1993. NACCESS, Computer Program. University College London: Department of Biochemistry Molecular Biology.
21. Ito H, Hamerman JA. 2012. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. European Journal of Immunology 42:176-185. doi:10.1002/eji.201141679,PMID:21956652
22. Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. The Journal of Experimental Medicine 212:287-295. doi:10.1084/jem.20142322,PMID:25732305
23. Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, Bertelsen S, Goate AM, Cruchaga C. 2014. ’sCoding variants in TREM2 increase risk for Alzheimer. Human Molecular Genetics 23:5838-5846. doi:10.1093/hmg/ddu277,PMID:24899047
24. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, et al. 2013. ’sVariant of TREM2 associated with the risk of Alzheimer. New England Journal of Medicine 368:107-116. doi:10.1056/NEJMoa1211103,PMID:23150908
25. Karplus PA, Diederichs K. 2012. Linking crystallographic model and data quality. Science 336:1030-1033. doi:10.1126/science.1218231,PMID:22628654
26. Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA. 2015. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. Journal of Neuroscience 35:3384-3396. doi:10.1523/JNEUROSCI.2620-14.2015,PMID:25716838
27. Kelker MS, Debler EW, Wilson IA. 2004a. Crystal structure of mouse triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.76 A. Journal of Molecular Biology 344:1175-1181. doi:10.1016/j.jmb.2004.10.009,PMID:15561137
28. Kelker MS, Foss TR, Peti W, Teyton L, Kelly JW, Wüthrich K, Wilson IA. 2004b. Crystal structure of human triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.47 A. Journal of Molecular Biology 342:1237-1248. doi:10.1016/j.jmb.2004.07.089,PMID:15351648
29. Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleó A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sánchez-Valle R, Antonell A, Ramirez A, et al. 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine 6:243ra86. doi:10.1126/scitranslmed.3009093,PMID:24990881
30. Kobayashi N, Karisola P, Peña-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ, Nagumo H, Chernova I, Zhu B, Sharpe AH, Ito S, Dranoff G, Kaplan GG, Casasnovas JM, Umetsu DT, Dekruyff RH, Freeman GJ. 2007. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27: 927-940. doi:10.1016/j.immuni.2007.11.011,PMID:18082433
31. Kober DL, Wanhainen KM, Johnson BM, Randolph DT, Holtzman MJ, Brett TJ. 2014. Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases. Protein Expression and Purification 96:32-38. doi:10.1016/j.pep.2014.01.015,PMID:24508568
32. Kober DL, Yurtsever Z, Brett TJ. 2015. Efficient mammalian cell expression and Single-step purification of extracellular glycoproteins for crystallization. Journal of Visualized Experiments 106:e53445. doi:10.3791/53445
33. Laskowski RA, Swindells MB. 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling 51:2778-2786. doi:10.1021/ci200227u,PMID:21919503
34. Le Ber I, De Septenville A, Guerreiro R, Bras J, Camuzat A, Caroppo P, Lattante S, Couarch P, Kabashi E, Bouya-Ahmed K, Dubois B, Brice A. 2014. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiology of Aging 35:2419.e23-2412.e25. doi:10.1016/j.neurobiolaging.2014.04.010
35. McDonald IK, Thornton JM. 1994. Satisfying hydrogen bonding potential in proteins. Journal of Molecular Biology 238:777-793. doi:10.1006/jmbi.1994.1334,PMID:8182748
36. Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, et al. 2016. Data publication with the structural biology data grid supports live analysis. Nature Communications 7: 10882. doi:10.1038/ncomms10882,PMID:26947396
37. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. 2007. Identification of Tim4 as a phosphatidylserine receptor. Nature 450:435-439. doi:10.1038/nature06307,PMID:17960135
38. Morin A, Eisenbraun B, Key J, Sanschagrin PC, Timony MA, Ottaviano M, Sliz P. 2013. Collaboration gets the most out of software. eLife 2:e01456. doi:10.7554/eLife.01456,PMID:24040512
39. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols 2:2212-2221. doi:10.1038/nprot.2007.321,PMID:17853878
40. Numasawa Y, Yamaura C, Ishihara S, Shintani S, Yamazaki M, Tabunoki H, Satoh JI. 2011. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. European Journal of Neurology 18:1179-1183. doi:10.1111/j.1468-1331.2010.03311.x,PMID:21834902
41. Otwinowski Z, Minor W. 1997. Processing of X-Ray Diffraction Data Collected in Oscillation Mode. New York: Academic Press.
42. Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L. 2003. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. The Journal of Experimental Medicine 198:669-675. doi:10.1084/jem.20030027,PMID:12925681
43. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L. 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. American Journal of Human Genetics 71:656-662. doi:10.1086/342259,PMID:12080485
44. Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, Yoon SY. 2015. Disease-Associated Mutations of TREM2 Alter the Processing of N-Linked Oligosaccharides in the Golgi Apparatus. Traffic 16:510-518. doi:10.1111/tra.12264,PMID:25615530
45. Phongsisay V, Iizasa E, Hara H, Yamasaki S. 2015. 3-O-sulfo-b-D-galactose moiety of endogenous sulfoglycolipids is a potential ligand for immunoglobulin-like receptor LMIR5. Molecular Immunology 63:595-599. doi:10.1016/j.molimm.2014.07.023,PMID:25172093
46. Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. 2016. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica 131:925-933. doi:10.1007/s00401-016-1533-5,PMID:26754641
47. Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. 2015. TREM2 sustains microglial expansion during aging and response to demyelination. The Journal of Clinical Investigation 125: 2161-2170. doi:10.1172/JCI77983,PMID:25893602
48. Quan DN, Cooper MD, Potter JL, Roberts MH, Cheng H, Jarvis GA. 2008. TREM-2 binds to lipooligosaccharides of Neisseria gonorrhoeae and is expressed on reproductive tract epithelial cells. Mucosal Immunology 1:229-238. doi:10.1038/mi.2008.1,PMID:19079182
49. Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, et al. 2013. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Molecular Neurodegeneration 8:19. doi:10.1186/1750-1326-8-19,PMID:23800361
50. Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Kauwe JSK. 2016. Assessment of the genetic variance of late-onset alzheimer’s disease. Neurobiology of Aging 41:200.e13-200.e20. doi:10.1016/j.neurobiolaging.2016.02.024
51. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Research 42:W320-W324. doi:10.1093/nar/gku316,PMID:24753421
52. Santiago C, Ballesteros A, Martínez-Muñoz L, Mellado M, Kaplan GG, Freeman GJ, Casasnovas JM. 2007. Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity 27:941-951. doi:10.1016/j.immuni.2007.11.008,PMID:18083575
53. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology 7:539. doi:10.1038/msb.2011.75,PMID:21988835
54. Sikkink LA, Ramirez-Alvarado M. 2008. Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. Biophysical Chemistry 135:25-31. doi:10.1016/j.bpc.2008.02.019,PMID:18395318
55. Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F. 2012. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119: 2799-2809. doi:10.1182/blood-2011-08-372425,PMID:22302738
56. Soragna D, Papi L, Ratti MT, Sestini R, Tupler R, Montalbetti L. 2003. An italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. Journal of Neurology, Neurosurgery & Psychiatry 74:825-826. doi:10.1136/jnnp.74.6.825-a,PMID:12754369
57. Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina Bordignon P, Meldolesi J. 2009. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. Journal of Neurochemistry 110: 284-294. doi:10.1111/j.1471-4159.2009.06130.x,PMID:19457124
58. Takahashi K, Rochford CD, Neumann H. 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. The Journal of Experimental Medicine 201:647-657. doi:10.1084/jem.20041611,PMID:15728241
59. Takegahara N, Takamatsu H, Toyofuku T, Tsujimura T, Okuno T, Yukawa K, Mizui M, Yamamoto M, Prasad DV, Suzuki K, Ishii M, Terai K, Moriya M, Nakatsuji Y, Sakoda S, Sato S, Akira S, Takeda K, Inui M, Takai T, et al. 2006. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nature Cell Biology 8:615-622. doi:10.1038/ncb1416,PMID:16715077
60. Tietjen GT, Gong Z, Chen CH, Vargas E, Crooks JE, Cao KD, Heffern CT, Henderson JM, Meron M, Lin B, Roux B, Schlossman ML, Steck TL, Lee KY, Adams EJ. 2014. Molecular mechanism for differential recognition of membrane phosphatidylserine by the immune regulatory receptor Tim4. PNAS 111:E1463-E1472. doi:10.1073/pnas.1320174111,PMID:24706780
61. Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. 2006. Cutting edge: TREM-2 attenuates macrophage activation. Journal of Immunology 177:3520-3524. doi:10.4049/jimmunol.177.6.3520,PMID:16951310
62. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. 2014. Altered microglial response to Ab plaques in APPPS1-21 mice heterozygous for TREM2. Molecular Neurodegeneration 9:20. doi:10.1186/1750-1326-9-20,PMID:24893973
63. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. 2015. ’sTREM2 lipid sensing sustains the microglial response in an Alzheimer. Cell 160:1061-1071. doi:10.1016/j.cell.2015.01.049,PMID:25728668
64. Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M. 2016. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. The Journal of Experimental Medicine 213:667-675. doi:10.1084/jem.20151948,PMID:27091843
65. Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC, Cella M, Gilfilan S, Colonna M, Kober DL, Brett TJ, Holtzman MJ. 2015. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. The Journal of Experimental Medicine 212:681-697. doi:10.1084/jem.20141732,PMID:25897174
66. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. 2016. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91:328-340. doi:10.1016/j.neuron.2016.06.015,PMID:27477018
67. Yoon SH, Lee YD, Ha J, Lee Y, Kim HH. 2012. TLT-1s, alternative transcripts of triggering receptor expressed on myeloid cell-like transcript-1 (TLT-1), Inhibits the triggering receptor expressed on myeloid cell-2 (TREM-2)-mediated signaling pathway during osteoclastogenesis. The Journal of Biological Chemistry 287:29620-29626. doi:10.1074/jbc.M112.351239,PMID:22761415
68. Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. 2016. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724-739. doi:10.1016/j.neuron.2016.05.003,PMID:27196974
69. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, et al. 2013. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153:707-720. doi:10.1016/j.cell.2013.03.030,PMID:23622250